News|Videos|November 6, 2023
PSMAfore: Lutetium-177–PSMA-617 in Metastatic CRPC
Shared insight from Rana McKay, MD, and the Oncology Brothers on updated data from PSMAfore and the use of Lutetium-177–PSMA-617 in patients with metastatic castration-resistant prostate cancer.
Advertisement
Advertisement
Related to this article
Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Aglatimagene Boosts Immune Infiltration in Localized Prostate Cancer
2
Rinatabart Sesutecan Shows Durable Responses in Platinum-Resistant Ovarian Cancer
3
Epcoritamab Plus R-CHOP Improves PFS in Newly Diagnosed DLBCL
4
Phase 3 Trial of Daraxonrasib Plus Zoldonrasib Begins in RAS G12D PDAC
5